HAVCR2 and myelodysplastic syndrome: Sabatolimab has demonstrated immuno-myeloid activity within a potential dual mechanism against AML and myelodysplastic syndrome (MDS) through reactivating the immune system to eliminate LSCs and blasts, as well as directly targeting TIM-3 on leukemic blasts to inhibit cancer cell proliferation [216].